Multiple myeloma (MM) accounts for up to 1% of all malignancies and up to 10% of all hematologic malignancies. Patients most commonly present with anemia; hypercalcemia; recurrent infections; and symptoms secondary to bone marrow infiltration, such as bone pain and pathologic fractures [1] . Extraosseous manifestations of MM are rare and found in <5% of patients; radiographic descriptions are limited [2] . Furthermore, the presence of plasmacytomas in patients with known MM suggests further dissemination of the disease, which indicates a worse prognosis [3] . The incidence of extraosseous myeloma may be increasing, likely due to longer patient survival and more-sensitive imaging modalities. Patients with extraosseous manifestations of MM have shorter overall survival and shorter progression-free intervals [3] . The radiologic descriptions of extraosseous myeloma are limited and are reviewed here with examples from our own institution.
Diagnosis of MM
The Mayo criteria [4] include the following:
1. M-protein in serum or urine less than 3 g/dL. 2. More than or equal to 10% monoclonal plasma cells from bone marrow aspirate. 3. Organ-tissue impairment, typically in the form of hypercalcemia, renal insufficiency, anemia, or bony lytic lesions.
Imaging Findings

Liver
Two common computed tomographic (CT) patterns have been reported in cases of hepatic involvement: (1) a single or a few focal hypoattenuating lesions, demonstrating minimal if any contrast enhancement, and (2) diffuse hepatic involvement with innumerable small low-attenuation lesions and hepatomegaly ( Figure 1 ). The most consistent CT finding reported is the lack of calcification [2] . Case reports, however, describe homogenous arterial phase enhancement, with complete washout on the portal venous phase to become hypodense relative to liver parenchyma [5] . However, the lesions may be low attenuation on all 3 phases (arterial, portal venous, and delayed) ( Figure 1 ). On noncontrast CT, the lesions can be hypodense to liver parenchyma ( Figure 2 ). Ultrasound demonstrates a target or bulls-eye lesion, with an echogenic center surrounded by a hypoechoic halo [6] . Hepatic plasmacytomas also can be heterogeneous and primarily hypoechoic on ultrasound ( Figure 1D ). Magnetic resonance imaging (MRI) has been reported to typically demonstrate homogeneous T2 hyperintensity and T1 hypointensity in cases of hepatic plasmacytomas [5, 6] . However, hyperintense T1 lesions also have been described, presumably reflecting high protein content, and enhancement is usually minimal reflecting the hypovascular nature of hepatic lesions [7] .
Pancreas
Pancreatic plasmacytoma lesions are most commonly solitary well-defined soft-tissue masses, with rare reports of multiple solid lesions or diffuse involvement, which causes lobulated enlargement of the pancreas [8] . Ultrasound most commonly demonstrates focal pancreatic lesions as hypoechoic solid masses ( Figure 3C ) [10] . CT demonstrates focal lesions with variable contrast enhancement. The majority of lesions demonstrate increased enhancement relative to pancreatic parenchyma, which is most conspicuous during arterial phase imaging [9] . The enhancement characteristics may be variable, with some cases demonstrating heterogeneous enhancement (Figures 3 and 4 ) [2, 10] . Enhancing lesions may mimic islet cell tumours, and hypoenhancing lesions can be mistaken for adenocarcinoma [7] . Larger lesions have been described that result in pancreatic duct dilatation and encase the adjacent celiac vessels, further mimicking adenocarcinoma [2] . MRI demonstrates myelomatous pancreatic masses as hyperintense on T2 and hypoto isointense on T1 relative to the pancreatic parenchyma. As with CT, gadolinium enhancement is usually seen but enhancement patterns are variable [9] .
Gastrointestinal and Peritoneal Findings
The small bowel is the most common site of myelomatous gastrointestinal involvement, followed by the stomach, colon, and esophagus. MM is most commonly seen as mural infiltration, which causes wall thickening and demonstrates variable enhancement ( Figure 5 ) [2, 9] . Involvement of the bowel can also manifest as homogeneous soft-tissue masses, which may be eccentric in location, lobulated, mural, or intraluminal [8] . The imaging findings may overlap those of lymphoma, and differentiation of the two by imaging may not be possible [2] . A review of the literature indicates that enhancing nodules are the most common peritoneal manifestation of extraosseous MM, but large heterogeneously enhancing mesenteric masses are also seen ( Figures 6, 7 , 8A and 8B) [11] . Omental and mesenteric masses may be bulky, demonstrating homogeneous soft-tissue attenuation, which may also mimic lymphoma. These soft-tissue masses commonly demonstrate low T2 signal [8] . Ascites may also be seen, which results in imaging characteristics similar to peritoneal carcinomatosis ( Figure 8 ) [12, 13] .
Adrenal Masses
Adrenal masses are rare, and descriptions are mostly limited to case reports. On CT, adrenal plasmacytomas are most commonly seen as heterogeneous, well-circumscribed, soft-tissue density lesions ( Figure 9 ) [14] . Larger lesions have been described to demonstrate central necrosis and heterogeneous enhancement. On MRI, heterogeneous signal intensity is seen on both T1-and T2-weighted sequences. Heterogeneous contrast enhancement is usually present, and, unlike adenomas, these lesions do not demonstrate signal dropout on opposed phase imaging [6] .
Renal and Retroperitoneal Findings
True renal plasma cell masses are uncommon. Limited examples describe a nonspecific mass arising from the kidney. Ultrasound examples describe a large hypoechoic heterogeneous renal mass that demonstrates soft-tissue attenuation isodense to renal parenchyma, with areas of necrosis on nonenhanced CT [7] . Contrast-enhanced CT demonstrates moderate and heterogeneous enhancement [11] . Solitary or multiple perirenal and retroperitoneal nodules are more commonly described, and these are usually shown to enhance with intravenous contrast administration [11] . We present a perirenal mass, which is hypoechoic on ultrasound and demonstrates mild heterogeneity and enhancement on CT ( Figure 10, A and B) . On T2-weighted MRI, the signal intensity is heterogeneous, with focal areas of high signal ( Figure 10C ). Retroperitoneal nodules demonstrate soft-tissue density on noncontrast CT and enhance with contrast administration. Perirenal nodules, which mimic melanoma metastases have been described [13] . Large retroperitoneal myelomatous masses may encase vessels similar to lymphoma ( Figure 11 ). Larger masses often demonstrate early arterial phase enhancement ( Figure 12) [6, 11] . Bulky retroperitoneal masses also have been described to cause mass effect on the kidneys and the renal collecting system [2] .
Genitourinary and Pelvis Findings
Descriptions of genitourinary MM are uncommon. Testicular infiltration may be seen on ultrasound as diffuse enlargement or as solitary or multiple hypoechoic testicular lesions [2, 8, 13] . The findings may mimic malignant and nonmalignant pathology, such as lymphoma and Figure 11 . Contrast-enhanced computed tomography image of a 55-year-old man, with nodular enhancing myelomatous mass (arrow) that encased the celiac artery and aorta. sarcoidosis. We describe a seminal vesicle myelomatous mass as an enhancing soft-tissue mass with central low attenuation on contrast-enhanced CT (Figure 13 ). Vaginal myelomatous masses also have been described as hyperenhancing soft-tissue lesions seen on CT [11] . Within the pelvis, conglomerate masses of enlarged lymph nodes are more commonly seen. These masses enhance on CT, with larger masses more likely to demonstrate heterogeneous attenuation and areas of low-density necrosis (Figures 14  and 15 ).
Biopsy and Treatment
When considering the variable and often nonspecific appearance of abdominal myeloma, biopsy is often used for diagnosis. As outlined above, abdominal and pelvic myelomatous lesions can mimic other malignancies or benign processes. The findings may resemble lymphoma when presenting as a retroperitoneal mass or when involving the gastrointestinal tract [15, 16] . The nonspecific and overlapping gastrointestinal and solid-organ manifestations illustrate the potential for misinterpretation in favor of more common malignant mimics. Amyloidosis or fungal infection may also present in the setting of MM or during chemotherapy, and, therefore, the presence of lymph-node enlargement or nodular hepatic involvement highlights the importance of pathologic diagnosis to rule out a benign alternative [11] . Patients who present with plasmacytomas secondary to disseminated MM receive chemotherapy as first-line treatment, with a response rate of approximately 65% (Figures 16 and 17 ) [17] . Patients who are eligible for autologous stem cell transplantation are first treated with chemotherapeutic induction agents for 3-4 months before bone marrow transplantation [17] .
Conclusion
Abdominal myeloma is uncommon but portends a relatively poor prognosis. The most common locations of extraosseous MM in the abdomen include the liver, pancreas, mesentery, adrenal glands, and retroperitoneum. The imaging findings are variable but generally consist of variably enhancing soft-tissue masses, with less predictable hepatic lesion enhancement. Extraosseous abdominal myeloma should be considered in the differential diagnosis of a patient with MM and who present with an intra-abdominal mass.
